Dizziness is a real, listed side effect of the weight-loss GLP-1s, reported by roughly 4% to 8% of people in their trials against 2% to 5% on placebo. The labels also show where some of it comes from: blood pressure that falls, especially in people already on blood-pressure tablets; fluid lost through vomiting and diarrhoea; and, for people with diabetes on other medicines, low blood sugar. Fainting is recorded too, but in under 1% of people.
This page reads the adverse-reaction sections of seven US labels on DailyMed, all opened on 2 November 2026. It reports what they record. It does not advise on what to do about dizziness; new, severe or persistent dizziness, or fainting, is for a clinician to assess.
Dizziness rates on each label
| Label (molecule) | Population and trial | Drug | Placebo |
|---|---|---|---|
| Wegovy 2.4 mg (semaglutide) | adults, weight trials (N=2,116 vs 1,261) | 8% | 4% |
| Wegovy 7.2 mg | adults, 7.2 mg trial (N=1,311 on 7.2 mg; 304 on 2.4 mg; 303 placebo) | 6% (7.2 mg) · 5% (2.4 mg) | 1% |
| Wegovy 2.4 mg | adolescents 12+, 68 weeks (N=133 vs 67) | 8% | 3% |
| Saxenda (liraglutide) | adults, five trials (N=3,384 vs 1,941) | 6.9% | 5.0% |
| Saxenda | adolescents 12+, 56 weeks (N=125 vs 126) | 10.4% | 3.2% |
| Zepbound 5 / 10 / 15 mg (tirzepatide) | adults, Studies 1 and 2, 72 weeks | 4% / 5% / 4% | 2% |
| Foundayo (orforglipron) | adults, pool of Trials 1 and 2 | 4% | 3% |
| Ozempic (semaglutide) | type 2 diabetes trials | listed among reactions above 0.4%, no rate given | — |
| Mounjaro (tirzepatide) | postmarketing reports | listed under nervous system disorders, no rate | — |
Labels: Wegovy effective 18 June 2026; Saxenda 25 February 2026; Zepbound 28 August 2026; Foundayo 29 July 2026; Ozempic 1 June 2026; Mounjaro 27 August 2026. Wegovy's 7.2 mg row counts "dizziness and dizziness postural" together. The Wegovy tablet section states that the types and frequency of common reactions in its 204-person trial "were similar" to the injection table, without its own dizziness figure. Doses are trial arms, not recommendations.
Two things stand out. Placebo arms report dizziness too, 1% to 5%, so roughly half or more of the dizziness in some trials would have happened anyway. And the adolescent figures are higher than the adult ones on both labels that report them: 8% on Wegovy and 10.4% on Saxenda.
Route one: blood pressure that falls
GLP-1 drugs lower blood pressure on average, which is reported as a benefit on GLP-1s and blood pressure. For some people it falls far enough to be felt. Wegovy's label is the most specific:
"Adverse reactions related to hypotension (hypotension, orthostatic hypotension, and decreased blood pressure) were reported in 1.3% of WEGOVY-treated adult patients versus 0.4% of placebo-treated patients and syncope was reported in 0.8% of WEGOVY-treated patients versus 0.2% of placebo-treated patients … Some reactions were related to gastrointestinal adverse reactions and volume loss associated with WEGOVY. Hypotension and orthostatic hypotension were more frequently seen in patients on concomitant antihypertensive therapy." — Wegovy label, 6.1
In Wegovy's adolescent trial, hypotension was 2.3% against 0%. Zepbound's adverse-reaction table lists hypotension (pooling orthostatic hypotension and decreased blood pressure) at 1%, 1% and 2% on 5, 10 and 15 mg against 0% on placebo. "Orthostatic" means the drop on standing up, the classic light-headed moment after getting out of a chair or bed.
Route two: fluid loss
Nausea, vomiting and diarrhoea are the most common GLP-1 side effects, and losing fluid is a known cause of dizziness. The labels treat the serious end of this as a warning: Zepbound's label has a section headed "Acute Kidney Injury Due to Volume Depletion", and Wegovy's notes that some of its low-blood-pressure reactions were related to "volume loss". The gastrointestinal rates are on GLP-1 nausea and GLP-1 diarrhoea.
Route three: low blood sugar
The patient leaflets for Mounjaro and Rybelsus list "dizziness or light-headedness" first among the signs of low blood sugar, and say the risk is higher when the GLP-1 is used with a sulfonylurea or insulin. In Wegovy's adult table, hypoglycaemia in people with type 2 diabetes was 6% against 2%; in Saxenda's type 2 diabetes trial, 12.6% against 6.6%. The labels' instruction to prescribers on those combinations is quoted on GLP-1 drug interactions.
When the leaflets say to get help
The Mounjaro and Rybelsus patient leaflets list "fainting or feeling dizzy" alongside swelling of the face, lips or throat, breathing problems, severe rash and a very rapid heartbeat as symptoms of a serious allergic reaction, and tell the reader to stop the medicine and "get medical help right away". That is the leaflets' wording, quoted; it is not this site's advice. Dizziness with any of those symptoms is an emergency in the leaflets' terms.
What the labels do not say
- How long it lasts. No label reports the duration of dizziness. What is known about the timing of side effects generally is on how long GLP-1 side effects last.
- Whether it is dose-related. Zepbound's three doses report 4%, 5% and 4%; Wegovy's 7.2 mg trial reports 6% against 5% at 2.4 mg. Neither shows a clear dose step.
- Vertigo. None of the labels read separates spinning vertigo from light-headedness. "Dizziness" in these tables is the reported term, whatever the person meant by it.
- Compounded products. Compounded semaglutide and tirzepatide have no label, so none of these rates was measured on them.
The full side-effect overview is on GLP-1 side effects; headache, which often travels with dizziness in reports, is on GLP-1 headache, and tiredness on GLP-1 fatigue.
Sources
US prescribing information and patient information on DailyMed, each opened 2 November 2026: Wegovy (effective 18 Jun 2026) section 6.1; Saxenda (25 Feb 2026) section 6.1, Tables 2 and 3; Zepbound (28 Aug 2026) section 6.1, Table 1, and section 5 (acute kidney injury due to volume depletion); Foundayo (29 Jul 2026) section 6.1; Ozempic (1 Jun 2026) section 6.1; Mounjaro (27 Aug 2026) section 6.2 and patient information; Rybelsus and Ozempic tablets (30 Jan 2026) patient information.